<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425708</url>
  </required_header>
  <id_info>
    <org_study_id>XYFY2017-KL043-01</org_study_id>
    <nct_id>NCT03425708</nct_id>
  </id_info>
  <brief_title>Effect of Hyperuricaemia on Chronic Renal Disease</brief_title>
  <official_title>Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First People's Hospital of Xuzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Affiliated Hospital of Xuzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to explore the best effective dose and adverse reaction of febuxostat in
      lowering serum uric acid to low level in patients with Chronic Renal Disease at different
      stages. To elucidate that low levels of serum uric acid can delay the progression of renal
      damage. Promote the application of anti uric acid drugs in the treatment of chronic renal
      failure and delay the progress of CKD in patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum uric acid</measure>
    <time_frame>up to 6 months</time_frame>
    <description>intravenous blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>up to 6 months</time_frame>
    <description>intravenous blood sampling</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Chronic Renal Disease</condition>
  <arm_group>
    <arm_group_label>Treatment group1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment of CKD patients with hyperuricaemia with conventional methods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20mg Febuxostat</intervention_name>
    <description>Participants take 20mg febuxostat pill once a day for at least six months.</description>
    <arm_group_label>Treatment group1</arm_group_label>
    <other_name>20mg Febuxostat pill group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40mg Febuxostat</intervention_name>
    <description>Participants take 40mg febuxostat pill once a day for at least six months.</description>
    <arm_group_label>Treatment group2</arm_group_label>
    <other_name>40mg Febuxostat pill group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-dialysis CKD patients with serum uric acid greater than 7mg/dl.

          -  eGFR≥15ml/min/1.73m².

          -  Low salt, low protein, low purine diet.

        Exclusion Criteria:

          -  Take drugs that raise blood uric acid at the same time.

          -  Patients with gout attacks.

          -  Patients with pregnant, lactating.

          -  Autosomal dominant polycystic kidney disease.

          -  Patients with poor general condition and multiple organ failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Sun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Sun, MD</last_name>
    <phone>15862158578</phone>
    <email>sundong126@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Sun, MD</last_name>
      <phone>15862158578</phone>
      <email>sundong126@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Stack A, Manolis AJ, Ritz E. Detrimental role of hyperuricemia on the cardio-reno-vascular system. Curr Med Res Opin. 2015;31 Suppl 2:21-6. doi: 10.1185/03007995.2015.1087984. Review.</citation>
    <PMID>26414733</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Bao X. Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms. Eur J Med Res. 2013 Jul 30;18:26. doi: 10.1186/2047-783X-18-26. Retraction in: Eur J Med Res. 2015;20:44.</citation>
    <PMID>23895583</PMID>
  </reference>
  <reference>
    <citation>Tsuruta Y, Kikuchi K, Tsuruta Y, Sasaki Y, Moriyama T, Itabashi M, Takei T, Uchida K, Akiba T, Tsuchiya K, Nitta K. Febuxostat improves endothelial function in hemodialysis patients with hyperuricemia: A randomized controlled study. Hemodial Int. 2015 Oct;19(4):514-20. doi: 10.1111/hdi.12313. Epub 2015 May 21.</citation>
    <PMID>25998500</PMID>
  </reference>
  <reference>
    <citation>Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, Endou H, Johnson RJ. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol. 2006 Jul;17(7):1791-5. Epub 2006 Jun 14.</citation>
    <PMID>16775029</PMID>
  </reference>
  <reference>
    <citation>Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005 May;67(5):1739-42.</citation>
    <PMID>15840020</PMID>
  </reference>
  <reference>
    <citation>Sellin L, Kielstein JT, de Groot K. [Hyperuricemia - more than gout : Impact on cardiovascular risk and renal insufficiency]. Z Rheumatol. 2015 May;74(4):322-8. doi: 10.1007/s00393-014-1481-1. Review. German.</citation>
    <PMID>25962453</PMID>
  </reference>
  <reference>
    <citation>Mancia G, Grassi G, Borghi C. Hyperuricemia, urate deposition and the association with hypertension. Curr Med Res Opin. 2015;31 Suppl 2:15-9. doi: 10.1185/03007995.2015.1087981. Review.</citation>
    <PMID>26414732</PMID>
  </reference>
  <reference>
    <citation>Miyata H, Takada T, Toyoda Y, Matsuo H, Ichida K, Suzuki H. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations. Front Pharmacol. 2016 Dec 27;7:518. doi: 10.3389/fphar.2016.00518. eCollection 2016.</citation>
    <PMID>28082903</PMID>
  </reference>
  <reference>
    <citation>Perez-Ruiz F, Becker MA. Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015;31 Suppl 2:9-14. doi: 10.1185/03007995.2015.1087980. Review.</citation>
    <PMID>26414731</PMID>
  </reference>
  <reference>
    <citation>Tan PK, Ostertag TM, Miner JN. Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep. 2016 Oct 7;6:34995. doi: 10.1038/srep34995.</citation>
    <PMID>27713539</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int. 2005 Jan;67(1):237-47.</citation>
    <PMID>15610247</PMID>
  </reference>
  <reference>
    <citation>Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009 Mar;21(2):132-7. doi: 10.1097/BOR.0b013e3283257b96. Review. Erratum in: Curr Opin Rheumatol. 2010 Jan;22(1):107.</citation>
    <PMID>19339923</PMID>
  </reference>
  <reference>
    <citation>Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S. Time to target uric acid to retard CKD progression. Clin Exp Nephrol. 2017 Apr;21(2):182-192. doi: 10.1007/s10157-016-1288-2. Epub 2016 Jun 23. Review.</citation>
    <PMID>27339448</PMID>
  </reference>
  <reference>
    <citation>Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis. 2018 Mar;71(3):362-370. doi: 10.1053/j.ajkd.2017.08.017. Epub 2017 Nov 11.</citation>
    <PMID>29132945</PMID>
  </reference>
  <reference>
    <citation>Falvello LR, Fernández S, Navarro R, Urriolabeitia EP. Reactivity of Pd(0) complexes with the phosphino ylide [Ph2PCH2PPh2=C(H)C(O)Me]. Molecular structure of [Pd(PPh2CHPPh2C(H)C(O)Me)2]. Inorg Chem. 2000 Jun 26;39(13):2957-60.</citation>
    <PMID>11232839</PMID>
  </reference>
  <reference>
    <citation>Kang DH, Ha SK. Uric Acid Puzzle: Dual Role as Anti-oxidantand Pro-oxidant. Electrolyte Blood Press. 2014 Jun;12(1):1-6. doi: 10.5049/EBP.2014.12.1.1. Epub 2014 Jun 30. Review.</citation>
    <PMID>25061467</PMID>
  </reference>
  <reference>
    <citation>Jalal DI, Decker E, Perrenoud L, Nowak KL, Bispham N, Mehta T, Smits G, You Z, Seals D, Chonchol M, Johnson RJ. Vascular Function and Uric Acid-Lowering in Stage 3 CKD. J Am Soc Nephrol. 2017 Mar;28(3):943-952. doi: 10.1681/ASN.2016050521. Epub 2016 Sep 12.</citation>
    <PMID>27620990</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uric Acid</keyword>
  <keyword>Febuxostat</keyword>
  <keyword>Chronic Renal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

